Publications by authors named "Anna V Tinker"

Claim this Profile
B
Bridging historical evidence and contemporary strategies in the adjuvant treatment of early-stage epithelial ovarian cancer.
Madeline Rhind, Corinne Maurice-Dror, Yvette Drew, Lien Hoang, Anna V Tinker

Int J Gynecol Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Toxicities of Adolescent and Young Adults Who Underwent Radiation Therapy for Cervix Cancer: A Cross-Sectional Analysis.
Andrew G Pritchard, Melanie Altas, Anna V Tinker, Iwa Kong, Karen Goddard

J Adolesc Young Adult Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis.
Pauline Corbaux, Benoit You, Tatsuo Kagimura, Rosalind M Glasspool, Iain McNeish, Anna V Tinker

Int J Gynecol Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma.
Yuen Yee Leung, Marta Llaurado-Fernandez, Anna Cameron, Annalyn Da-Anoy, Linda C Cook, Anna V Tinker

J Gynecol Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in female cancer diagnostic billing rates over the COVID-19 period in the Ontario Health Insurance Plan.
Deanna McLeod, Ilidio Martins, Anna V Tinker, Amanda Selk, Christine Brezden-Masley

Ther Adv Med Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.
Ursula A Matulonis, Jørn Herrstedt, Amit Oza, Sven Mahner, Andrés Redondo, Anna V Tinker

Gynecol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.
Whitney S Graybill, Ignace Vergote, Bhavana Pothuri, Maarit Anttila, David M O'Malley, Anna V Tinker

J Comp Eff Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Giorgio Valabrega, Bhavana Pothuri, Ana Oaknin, Whitney S Graybill, Ana Beatriz Sánchez, Anna V Tinker

Gynecol Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
Claire F Friedman, Anishka D'Souza, Diana Bello Roufai, Anna V Tinker, Maria de Miguel

Gynecol Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.
Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier, Jubilee Brown, Anna V Tinker

Clin Cancer Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.
Thierry André, Dominique Berton, Giuseppe Curigliano, Renaud Sabatier, Anna V Tinker

JAMA Netw Open· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
Pauline Corbaux, Benoit You, Rosalind M Glasspool, Nozomu Yanaihara, Anna V Tinker

Eur J Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer.
Ana Oaknin, Lucy Gilbert, Anna V Tinker, Jubilee Brown, Cara Mathews

Future Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
Todd M Bauer, Kathleen N Moore, Janet S Rader, Fiona Simpkins, Alain C Mita, Anna V Tinker

Target Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD8 + T cell infiltration is associated with improved survival and negatively correlates with hypoxia in clear cell ovarian cancer.
Nancy Guo, Aijun Yang, Fabiha Binte Farooq, Shreena Kalaria, Elena Moss, Anna V Tinker

Sci Rep· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer.
Ana C Veneziani, Clare Scott, Matthew J Wakefield, Anna V Tinker, Stephanie Lheureux

Ther Adv Med Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer.
Anna V Tinker, Neesha C Dhani, Prafull Ghatage, Deanna McLeod, Vanessa Samouëlian

Ther Adv Med Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes" [Gynecologic Oncology, Volume 157, Issue 1, April 2020, Pages 36-45].
Stephanie A Scott, Marta Llaurado Fernandez, Hannah Kim, Laurie Elit, Melica Nourmoussavi, Anna V Tinker

Gynecol Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline Testing and Somatic Tumor Testing for Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?
Janice S Kwon, Anna V Tinker, Jennifer Santos, Katie Compton, Sophie Sun

JCO Precis Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cervical cancer patient reported gastrointestinal outcomes: intensity/volumetric modulated vs. 3D conformal radiation therapy.
Ryan Urban, Justin Wong, Peter Lim, Susan Zhang, Ingrid Spadinger, Anna V Tinker

J Gynecol Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.
Anna V Tinker, Alon D Altman, Marcus Q Bernardini, Prafull Ghatage, Lilian T Gien

Curr Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.
John Hilton, Karen Gelmon, Philippe L Bedard, Dongsheng Tu, Hong Xu, Anna V Tinker

Nat Commun· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment and outcomes in undifferentiated and dedifferentiated endometrial carcinoma.
Sarah Nicole Hamilton, Anna V Tinker, Janice Kwon, Peter Lim, Iwa Kong

J Gynecol Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.
Karolin Heinze, Tayyebeh M Nazeran, Sandra Lee, Pauline Krämer, Evan S Cairns, Anna V Tinker

J Pathol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
Ana Oaknin, Lucy Gilbert, Anna V Tinker, Jubilee Brown, Cara Mathews

J Immunother Cancer· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis